Background: We hypothesized that chronic renal parenchymal disease may predispose to acute renal failure (ARF), facilitating the induction of hypoxic medullary tubular injury. Methods: To induce chronic renal parenchymal injury, rats underwent sham operation (control) or bilateral 50-min clamping of the renal artery [ischemia-reperfusion (IR)]. One or 3 months later, both groups were subjected to an ARF protocol, consisting of radiocontrast and the inhibition of prostaglandin and nitric oxide synthesis. Renal function and morphology were determined 24 h later. Results: Chronic tubulointerstitial changes (fibrosis, atrophy and hypertrophy) in the IR group correlated with baseline tubular function, but glomerular function was preserved. Functional deterioration after the ARF protocol was only marginally more pronounced in the IR group, and the degree of medullary acute tubular necrosis (ATN) was unaffected by prior IR. The extent of both tubular necrosis and chronic tubulointerstitial changes independently predicted the acute decline in renal function. Immunostaining of IR kidneys disclosed critically low medullary pO2 (determined by pimonidazole adducts), regional hypoxic cell response (hypoxia-inducible factors) and upregulation of endothelin-B receptors. Conclusions: Compensatory changes result in normal plasma creatinine 1 and 3 months after IR, despite diminished tubular function. Preexisting renal disease only marginally predisposes to ARF, and the extent of ATN is not significantly enhanced. These findings illustrate the complex interaction between chronic and acute renal injury and dysfunction and parallel the difficulty of their assessment in the clinical practice. Adaptive cellular responses to chronic hypoxia in conjunction with parenchymal loss and decreased oxygen demand might alleviate acute hypoxic injury.

Keywords:
Kidney failure, acute, Kidney failure, chronic, Ischemia-reperfusion, Hypoxia, Medulla, Radiologic contrast media, Hypoxia-inducible factor, Endothelin-B receptors, Pimonidazole
1.
Boucher BA, Coffey BC, Kuhl DA,Tolley EA, Fabian TC: Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides. Am J Surg 1990;160:473–480.
2.
Lautin EM, Freeman NJ, Schoenfeld AH, Bakal CW, Haramati N, Friedman AC, Lautin JL, Braha S, Kadish EG, Sprayregen S: Radiocontrast-associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol 1991;157:49–58.
3.
Novis BK, Roizen MF, Aronson S, Thisted RA: Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 1994;78:143–149.
4.
Rich MW, Crecelius CA: Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990;150:1237–1242.
5.
Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259–2264.
6.
Chertow GM, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F, Daley J: Preoperative renal risk stratification. Circulation 1997;95:878–884.
7.
Silvester W, Bellomo R, Cole L: Epidemiology, management, and outcome of severe acute renal failure of critical illness in Australia. Crit Care Med 2001;29:1910–1915.
8.
Godet G, Fleron MH, Vicaut E, Zubicki A: Risk factors for acute postoperative renal failure in thoracic or thoracoabdominal aortic surgery: a prospective study. Anesth Analg 1997;85:1227–1232.
9.
Andersson LG, Ekroth R, Bratteby LE: Acute renal failure after coronary surgery – A study of incidence and risk factors in 2,009 consecutive patients. Thorac Cardiovasc Surg 1993;41:237–241.
10.
Brezis M, Rosen S: Hypoxia of the renal medulla – Its implications for disease. N Engl J Med 1995;332:647–655.
11.
Heyman SN, Lieberthal W, Rogiers P, Bonventre JV: Animal models of acute tubular necrosis. Curr Opin Crit Care 2002;8:526–534.
12.
Priyadarshi A, Periyasamy S, Burke TJ, Britton SL, Malhotra D, Shapiro JI: Effects of reduction of renal mass on renal oxygen tension and erythropoietin production in the rat. Kidney Int 2002;61:542–546.
13.
Basile DP, Danohoe D, Roethe K, Osborn JL: Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol 2001;281:F887–F899.
14.
Basile DP, Donohoe DL, Roethe K, Mattson DL: Chronic renal hypoxia after acute ischemic injury: effects of L-arginine on hypoxia and secondary damage. Am J Physiol 2003;284:F338–F348.
15.
Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M: Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994;94:1069–1075.
16.
Heyman SN, Rosen S, Brezis M: The renal medulla: life at the edge of anoxia. Blood Purif 1997;15:232–242.
17.
Heyman SN, Fuchs S, Yafe R, Beeri R, Elazarian L, Brezis M, Rosen S: Renal microcirculation and tissue damage during acute ureteral obstruction: the effect of saline infusion, indomethacin and radiocontrast. Kidney Int 1997;51:653–663.
18.
Rosenberger C, Heyman SN, Rosen S, Gruber G, Goldfarb M, Griethe W, Frei U, Bachmann S, Eckardt KU: Upregulation of HIF in acute renal failure: evidence for a protective transcriptional response to hypoxia. Kidney Int 2005;67:531–542.
19.
Heyman SN, Brezis M, Reubinoff CA, Greenfeld Z, Lechene C, Epstein F, Rosen S: Acute renal failure with selective medullary injury in the rat. J Clin Invest 1988;82:401–412.
20.
Heyman SN, Brezis M, Epstein FH, Spokes K, Silva P, Rosen S: Early renal medullary hypoxic injury from radiocontrast and indomethacin. Kidney Int 1991;40:632–642.
21.
Semenza G: Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993–998.
22.
Maxwell P: HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol 2003;14:156–159.
23.
Heyman SN, Rosenberger C, Rosen S: Erythropoietin: a potential remedy for renal tubular injury? Kidney Int 2004;65:737–738.
24.
Jelkmann W, Wagner K: Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004;83:673–686.
25.
Nath KA, Vercellotti GM, Grande JP, Miyoshi H, Paya CV, Manivel JC, Haggard JJ, Croatt AJ, Payne WD, Alam J: Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. Kidney Int 2001;59:106–117.
26.
Gonzalez-Michaca L, Farrugia G, Croatt AJ, Alam J, Nath KA: Heme: A determinant of life and death in renal tubular epithelial cells. Am J Physiol 2004;286:F370–F377.
27.
Gurbanov K, Rubinstein I, Hoffman A, Abassi Z, Better O, Winaver J: Differential regulation of renal regional blood flow by endothelin-1. Am J Physiol 1996;271:F1166–F1172.
28.
Francis BN, Abassi Z, Heyman SN, Winaver J, Hoffman A: Differential regulation of ETA and ETB in the renal tissue of rats with compensated and decompensated heart failure. J Cardiovasc Pharmacol 2004;44(suppl 1):S362–S365.
29.
Heyman SN, Abassi Z, Khamaisi M, Shina A, Goldfarb M, Rosen S Rosenberger C: Diabetes predisposes to medullary hypoxia with activation of hypoxia inducible factors (HIF) and upregulation of endothelin-B receptors (ETB). J Am Soc Nephrol 2004;15:468A.
30.
Grimshaw MJ, Naylor S, Balkwill FR: Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells. Mol Cancer Ther 2002;1:1273–1281.
31.
Forbes JM, Hewitson TW, Becker GJ, Jones CL: Ischemic acute renal failure: long-term histology of cell and matrix changes in the rat. Kidney Int 2000;57:2375–2385.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.